A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

In 2021, the FDA ap­proved Bris­tol My­ers Squibb’s Breyanzi for some adult lym­phoma pa­tients, mak­ing it the third CAR-T ther­a­py to be­come com­mer­cial­ly avail­able. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER